Skan swings to CHF 8.3 mln loss as sales fall on vaccine project delays

Skan Group reported a net loss of CHF 8.3 million for the first half of 2025, a sharp reversal from a CHF 14.7 million profit a year prior, with net sales dropping 17.8% and EBITDA plummeting 95.7% due to project delays in vaccine-related lines. Despite the significant decline in profitability, the Swiss cleanroom equipment maker saw strong operational indicators, including a 20.2% increase in order intake to CHF 213 million, a record order backlog of CHF 386.4 million, and improved operating and free cash flow. Skan maintained its full-year 2025 guidance for mid-teens percentage sales growth and a 14% to 16% EBITDA margin, further signaling strategic expansion with two bank-financed acquisitions post-reporting period.

Analysis

Skan Group reported a severe contraction in profitability for the first half of 2025, swinging to a net loss of CHF 8.3 million from a CHF 14.7 million profit in the prior year, driven by a 17.8% decline in net sales to CHF 134.6 million due to project delays in its vaccine-related business lines. The impact on margins was dramatic, with EBITDA falling 95.7% to just CHF 0.9 million. However, these backward-looking results are sharply contrasted by strong forward-looking indicators. Order intake grew by 20.2% to CHF 213 million, and the order backlog surged 21.4% to a record high of CHF 386.4 million, suggesting that the H1 sales decline is a matter of revenue recognition timing rather than a fundamental demand issue. This view is reinforced by management's decision to maintain its full-year 2025 guidance for mid-teens percentage sales growth and an EBITDA margin between 14% and 16%, implying a significant operational ramp-up in the second half. Furthermore, the company's cash flow improved, with operating cash flow reaching CHF 22.6 million and free cash flow turning positive at CHF 9.2 million, supported by a substantial increase in advance payments from customers. The post-period acquisitions of Metronik and ABC Transfer, financed through bank loans, signal an ongoing commitment to strategic expansion despite the temporary earnings pressure and a slightly reduced equity ratio of 48.1%.

Key Decisions for Investors

• Investors should look beyond the stark H1 2025 earnings miss and focus on the record order backlog, which suggests a strong potential for revenue and profit recovery in the second half of the year.
• The primary risk is execution; the investment case hinges on management's ability to convert the backlog and meet its reaffirmed full-year guidance, making any updates on project timelines a critical monitoring point.
• Consider the recent debt-financed acquisitions, which, while strategically sound, increase leverage and financial risk, requiring scrutiny of the company's ability to integrate these new assets and manage its balance sheet effectively.